Ma Ai Thanda Han
- Assistant Clinical Professor, Internal Medicine
Contact
- (602) 827-2078
- COLLEGE OF MEDICINE PHX
- hanm@arizona.edu
Bio
No activities entered.
Interests
No activities entered.
Courses
No activities entered.
Scholarly Contributions
Journals/Publications
- Aboona, M. B., Faulkner, C., Rangan, P., Ng, C. H., Huang, D. Q., Muthiah, M., Nevah Rubin, M. I., Han, M. A., Fallon, M. B., Kim, D., Chen, V. L., & Wijarnpreecha, K. (2024). Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study. Liver International. doi:10.1111/liv.15880
- Robertson, W. A., Nathan, R., Fallon, M., Wijarnpreecha, K., Thanda Han, M. A., & Nevah Rubin, M. I. (2023). S3425 Alect2 Amyloidosis as a Unique Cause of Liver Dysfunction. American Journal of Gastroenterology, 118(10S), S2261-S2262. doi:10.14309/01.ajg.0000963340.93949.0b
- Han, M. A., & Pyrsopoulos, N. (2021). Emerging Therapies for Alcoholic Hepatitis.. Clinics in liver disease, 25(3), 603-624. doi:10.1016/j.cld.2021.03.006More infoThe incidence of alcoholic hepatitis is increasing while the mortality rate remains high. The single current available therapy for severe alcoholic hepatitis is administration of corticosteroids for patients with severe alcoholic hepatitis, which has demonstrated limited benefits, providing a short-term mortality benefit with a marginal response rate. There is a need for developing safe and effective therapies. This article reviews novel therapies targeting various mechanisms in the pathogenesis of alcoholic hepatitis, such as the gut-liver axis, inflammatory cascade, oxidative stress, and hepatic regeneration. Current ongoing clinical trials for alcoholic hepatitis also are described.
